Danish allergy specialist ALK-Abello (ALKB: DC) has announced that Sanofi (Euronext: San) boss Carsten Hellmann is to become its new president and chief executive.
Mr Hellmann is currently executive vice president and member of the executive committee of French pharma major Sanofi and chief executive of its animal health arm Merial, which has annual sales of 2.6 billion euros and more than 7,000 employees worldwide.
Before joining Sanofi, the 52-year-old held executive positions in global health care and biopharmaceutical companies including Chr Hansen and Nunc Group
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze